This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients
suffering from a malignant brain tumor called glioblastoma having a first or second
progression can be included. They will be randomized to RT or RT + APG101.
APG101 is a fusion protein (similar to an antibody) and will be administered as a weekly
infusion. Patients can stay in this study as long as they benefit from the participation (no
fixed end).
In this trial, 30-35 sites in Germany, Austria and Russia take part.